Press Release

Dravet Syndrome Market Robust Expansion by Top Key Manufactures | Worldwide Overview by Size, Share, Trends, Segments

Dravet Syndrome Market Development, Key Opportunity, Application and Forecast to 2024

Proactive role played by regulatory bodies in approving novel drugs will fuel the global Dravet syndrome market growth during the forecast period. Dravet syndrome is a severe form of epilepsy that occurs in the first year of life and becomes a lifelong condition characterized by frequent and prolonged seizure episodes. It is a rare disorder, affecting 1 in every 15,700 Americans, according to the National Institutes of Health. Since it’s a rare disease, it requires unique treatment methods and many companies and institutions are coming to the fore with novel therapies. They are receiving encouragement from regulatory bodies such as the Food and Drug Administration (FDA) of the US. For example, the FDA, for the first time, cleared a cannabis-derived purified drug called epidiolex in June 2018. Such supportive regulatory policies are expected to emerge as one of the key Dravet syndrome market trends in the forthcoming years.

For more information in the analysis of this report, visit:

Monopoly of a Few Key Players to Stiffen Competition

Stiff competition is anticipated to emerge in this burgeoning market as the market share is held by a limited number companies. These competitors are solely focusing on enhancing their R&D capacities to bring out new and innovative product offerings.

Key Industry Developments:

  • July 2019: Epygenix Therapeutics, Inc., a biopharmaceutical company for Dravet syndrome, received the FDA’s Investigational New Drug Application (IND) approval for the Phase I of its 2-period, placebo-controlled study for treatment of Dravet syndrome. The study aims at understanding the efficacy of the company’s EPX-100 drug on fasting healthy subjects after a high-fat meal.
  • July 2018: Takeda Pharmaceutical Company and Ovid Therapeutics announced the initiation of their collaborative three clinical programs. One of the trials in this program is the study of pediatric patients suffering from Dravet syndrome and Lennox-Gastaut syndrome. The aim of the study is to investigate the modulation of the N-Methyl-D-Aspartate (NMDA) signaling receptor, which has been identified as a causative factor in many neurological conditions. 

Request a Sample Copy of the Global Dravet Syndrome Market Research Report:

Prominent Players Profiled in the Dravet Syndrome Market Report:

  • Zogenix
  • Epygenix Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • PTC Therapeutics
  • GW Pharmaceuticals plc.
  • Ovid Therapeutics

Global Dravet Syndrome Market Segmentation

By Treatment

  • Drugs
  • Vagus Nerve Stimulation (VNS)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

More Trending Topics From Fortune Business [email protected]

Pulmonary Drug Delivery Systems Market Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2026

Testosterone Test Kits Market Global Analysis, Opportunities and Forecast To 2026

Urology Implants and Devices Market: 2020 Potential Growth, Size, Industry Outlook, Competitive Landscape, And Global Forecast To 2026

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *